1
|
Collet C, Munhoz D, Mizukami T, Sonck J, Matsuo H, Shinke T, Ando H, Ko B, Biscaglia S, Rivero F, Engstrøm T, Arslani K, Leone AM, van Nunen LX, Fearon WF, Christiansen EH, Fournier S, Desta L, Yong A, Adjedj J, Escaned J, Nakayama M, Eftekhari A, Zimmermann FM, Sakai K, Storozhenko T, da Costa BR, Campo G, West NE, De Potter T, Heggermont W, Buytaert D, Bartunek J, Berry C, Collison D, Johnson T, Amano T, Perera D, Jeremias A, Ali Z, Pijls NH, De Bruyne B, Johnson NP. Influence of Pathophysiologic Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes. Circulation 2024; 150:586-597. [PMID: 38742491 PMCID: PMC11335079 DOI: 10.1161/circulationaha.124.069450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 05/10/2024] [Indexed: 05/16/2024]
Abstract
BACKGROUND Diffuse coronary artery disease affects the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiologic coronary artery disease patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularization and procedural outcomes. METHODS This prospective, investigator-initiated, single-arm, multicenter study enrolled patients with at least one epicardial lesion with an FFR ≤0.80 scheduled for PCI. Manual FFR pullbacks were used to calculate PPG. The primary outcome of optimal revascularization was defined as an FFR ≥0.88 after PCI. RESULTS A total of 993 patients with 1044 vessels were included. The mean FFR was 0.68±0.12, PPG 0.62±0.17, and the post-PCI FFR was 0.87±0.07. PPG was significantly correlated with the change in FFR after PCI (r=0.65 [95% CI, 0.61-0.69]; P<0.001) and demonstrated excellent predictive capacity for optimal revascularization (area under the receiver operating characteristic curve, 0.82 [95% CI, 0.79-0.84]; P<0.001). FFR alone did not predict revascularization outcomes (area under the receiver operating characteristic curve, 0.54 [95% CI, 0.50-0.57]). PPG influenced treatment decisions in 14% of patients, redirecting them from PCI to alternative treatment modalities. Periprocedural myocardial infarction occurred more frequently in patients with low PPG (<0.62) compared with those with focal disease (odds ratio, 1.71 [95% CI, 1.00-2.97]). CONCLUSIONS Pathophysiologic coronary artery disease patterns distinctly affect the safety and effectiveness of PCI. PPG showed an excellent predictive capacity for optimal revascularization and demonstrated added value compared with an FFR measurement. REGISTRATION URL: https://www.clinicaltrials.gov; Unique identifier: NCT04789317.
Collapse
Affiliation(s)
- Carlos Collet
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Daniel Munhoz
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
- Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy (D.M.)
| | - Takuya Mizukami
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
- Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan (T.M.)
| | - Jeroen Sonck
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Hitoshi Matsuo
- Department of Cardiovascular Medicine, Gifu Heart Center, Japan (H.M.)
| | - Toshiro Shinke
- Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan (T. Shinke, K.S.)
| | - Hirohiko Ando
- Department of Cardiology, Aichi Medical University, Japan (H.A., T.A.)
| | - Brian Ko
- Monash Cardiovascular Research Centre, Monash University and Monash Heart, Monash Health, Clayton, Victoria, Australia (B.K.)
| | - Simone Biscaglia
- Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Italy (S.B., G.C.)
| | - Fernando Rivero
- Cardiac Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain (F.R.)
| | - Thomas Engstrøm
- Rigshospitalet, University of Copenhagen, Denmark (T.E., K.A.)
| | - Ketina Arslani
- Rigshospitalet, University of Copenhagen, Denmark (T.E., K.A.)
| | - Antonio Maria Leone
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy (A.M.L.)
- IRCCS, Catholic University School of Medicine, Largo A. Gemelli, Rome, Italy (A.M.L.)
- Center of Excellence in Cardiovascular Diagnostics and Therapeutic, Ospedale Fabenefratelli Isola Tiberina Gemelli Isola, Rome, Italy (A.M.L.)
| | - Lokien X. van Nunen
- Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands (L.X.v.N.)
| | - William F. Fearon
- Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine and VA Palo Alto Health Care System, Palo Alto, CA (W.F.F.)
| | | | - Stephane Fournier
- Department of Cardiology, University Hospital of Lausanne, Switzerland (S.F., B.D.B.)
| | - Liyew Desta
- Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden (L.D.)
| | - Andy Yong
- Concord Repatriation General Hospital, University of Sydney, New South Wales, Australia (A.Y.)
| | - Julien Adjedj
- Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France (J.A.)
| | - Javier Escaned
- Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Madrid, Spain (J.E.)
| | | | - Ashkan Eftekhari
- Department of Cardiology, Aalborg University Hospital, Denmark (A.E.)
| | - Frederik M. Zimmermann
- Department of Cardiology, Catharina Hospital Eindhoven, the Netherlands (F.M.Z., N.H.J.P.)
| | - Koshiro Sakai
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
- Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan (T. Shinke, K.S.)
| | - Tatyana Storozhenko
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
- Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine (T. Storozhenko)
| | - Bruno R. da Costa
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK (B.R.d.C.)
- Clinical Epidemiology & Health Care Research, Institute of Health Policy and Management Evaluation, University of Toronto, Canada (B.R.d.C.)
| | - Gianluca Campo
- Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Italy (S.B., G.C.)
| | | | - Tom De Potter
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Ward Heggermont
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Dimitri Buytaert
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Jozef Bartunek
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
| | - Colin Berry
- School of Cardiovascular and Metabolic Health, University of Glasgow, UK (C.B., D.C.)
- NHS Golden Jubilee Hospital, Clydebank, UK (C.B., D.C.)
| | - Damien Collison
- School of Cardiovascular and Metabolic Health, University of Glasgow, UK (C.B., D.C.)
- NHS Golden Jubilee Hospital, Clydebank, UK (C.B., D.C.)
| | - Thomas Johnson
- University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK (T.J.)
| | - Tetsuya Amano
- Department of Cardiology, Aichi Medical University, Japan (H.A., T.A.)
| | - Divaka Perera
- School of Cardiovascular Medicine and Sciences, St Thomas’ Hospital Campus, King’s College London, UK (D.P.)
| | - Allen Jeremias
- St Francis Hospital and Heart Center, Roslyn, NY (A.J., Z.A.)
| | - Ziad Ali
- St Francis Hospital and Heart Center, Roslyn, NY (A.J., Z.A.)
| | - Nico H.J. Pijls
- Department of Cardiology, Catharina Hospital Eindhoven, the Netherlands (F.M.Z., N.H.J.P.)
| | - Bernard De Bruyne
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium (C.C., D.M., T.M., J.S., K.S., T. Storozhenko, T.D.P., W.H., D.B., J.B., B.D.B.)
- Department of Cardiology, University Hospital of Lausanne, Switzerland (S.F., B.D.B.)
| | - Nils P. Johnson
- Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX (N.P.J.)
| |
Collapse
|